

Evolution to Breakthrough in Lung and Updates in H&N Cancer Treatment with Immunotherapy

Friday, 17 November 2017

12:45 - 14:15

Satellite Symposium Sponsored by MSD

CHAIR

Tony S. K. Mok

Li Shu Fan Medical Foundation Professor and Chair of Clinical Oncology The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong

FACULTY

Kevin J. Harrington

Joint Head, Division of Radiotherapy and Imaging Professor in Biological Cancer Therapies Institute of Cancer Research London, United Kingdom

Rolf A. Stahel

Head, Center for Lung and Thoracic Oncology University Hospital Zurich Zurich, Switzerland

MSD Pharma (Singapore) Pte. Ltd. 150 Beach Road #31-00 Gateway West Singapore 189720 Tel: 6508 8400 Fax: 6296 0005 http://www.msd-singapore.com

Suntec Singapore Convention & Exhibition Centre Hall 405, Level 4 Suntec City, Singapore

Chair: Tony S. K. Mok (Hong Kong)

AGENDA		
12:45 - 12:50	Welcome, Introduction, and Objectives	Tony S. K. Mok
12:50 - 13:15	From Dusk to Dawn: A New Era in the Treatment of Advanced Non-Small Cell Lung Cancer Arises	Rolf A. Stahel
13:15 – 13:30	Future Direction of Immunotherapies in NSCLC	Tony S. K. Mok
13:30 – 13:55	Immune Checkpoint Inhibitors vs Standard of Care for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Kevin J. Harrington
13:55 – 14:10	Case Studies – H&N Cancer	Kevin J. Harrington
14:10 - 14:15	Summary and Closing Remarks	Tony S. K. Mok

Visit us at the MSD Exhibition Booth A10 on Level 4 for more information

Copyright © 2017 MSD Pharma (Singpaore) Pte Ltd., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. ONCO-1234203-0000 10/17

MSD Oncology